Bicara Therapeutics (NASDAQ:BCAX) Stock Gets Price Target Trim from Morgan Stanley

Bicara Therapeutics (NASDAQ:BCAX) had its target price lowered by Morgan Stanley from $41.00 to $30.00 in a research note released on Tuesday morning,Benzinga reports. The firm currently has an overweight rating on the stock.

A number of other analysts have also commented on BCAX. BMO Capital Markets started coverage on Bicara Therapeutics in a report on Tuesday, August 18th. They issued an “outperform” rating and a $35.00 target price for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Bicara Therapeutics in a report on Friday, October 2nd. BTIG Research lowered their price target on Bicara Therapeutics from $39.00 to $37.00 and set a “buy” rating on the stock in a report on Tuesday. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Bicara Therapeutics in a research report on Thursday, September 10th. Finally, Wedbush reduced their price objective on Bicara Therapeutics from $33.00 to $24.00 and set an “outperform” rating for the company in a report on Thursday, October 29th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, Bicara Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $30.33.

Bicara Therapeutics Price Performance

Shares of BCAX opened at $10.11 on Tuesday. Bicara Therapeutics has a twelve month low of $7.87 and a twelve month high of $30.99. The firm has a 50 day moving average of $17.10 and a 200 day moving average of $20.81.

Bicara Therapeutics (NASDAQ:BCAX) last released its quarterly earnings data on Monday, November 9th. The company reported ($1.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.82) by ($0.22). On average, equities research analysts predict that Bicara Therapeutics will post -3.82 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Ryan Cohlhepp sold 17,500 shares of the stock in a transaction that occurred on Tuesday, September 8th. The shares were sold at an average price of $22.90, for a total transaction of $400,750.00. Following the transaction, the chief executive officer owned 181,641 shares in the company, valued at $4,159,578.90. This represents a 8.79% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 13.80% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Bicara Therapeutics

A number of large investors have recently added to or reduced their stakes in the stock. Russell Investments Group Ltd. raised its stake in Bicara Therapeutics by 33.3% during the 3rd quarter. Russell Investments Group Ltd. now owns 44,425 shares of the company’s stock valued at $827,000 after buying an additional 11,086 shares during the last quarter. Nan Fung Trinity HK Ltd. boosted its stake in shares of Bicara Therapeutics by 49.9% in the 3rd quarter. Nan Fung Trinity HK Ltd. now owns 427,885 shares of the company’s stock worth $7,963,000 after buying an additional 142,390 shares during the last quarter. Alps Advisors Inc. boosted its stake in shares of Bicara Therapeutics by 32.5% in the 3rd quarter. Alps Advisors Inc. now owns 87,692 shares of the company’s stock worth $1,632,000 after buying an additional 21,510 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Bicara Therapeutics in the 3rd quarter worth $63,000. Finally, Profund Advisors LLC grew its holdings in shares of Bicara Therapeutics by 7.2% in the third quarter. Profund Advisors LLC now owns 16,880 shares of the company’s stock worth $314,000 after acquiring an additional 1,140 shares during the period.

Key Headlines Impacting Bicara Therapeutics

These are some of the BCAX headlines that stood out recently:

• Positive Sentiment: HC Wainwright kept its Buy rating on BCAX and a $36 price target, which could support investor optimism despite the target reduction from $42. HC Wainwright target update
• Negative Sentiment: Stifel Nicolaus and Morgan Stanley reportedly cut their BCAX price targets, and BTIG Research issued a pessimistic forecast. These actions may weigh on sentiment; the provided headlines do not specify the revised targets or detailed rationale. Stifel target cut Morgan Stanley target cut BTIG forecast
• Negative Sentiment: HC Wainwright’s 2027 estimates project continuing quarterly losses, including a full-year loss of $4.63 per share. Expectations of ongoing losses can be a headwind for a clinical-stage biotech, even with the firm’s Buy rating.

Bicara Therapeutics Company Profile

Bicara Therapeutics is a clinical-stage biopharmaceutical company developing treatments for solid tumors. Its research focuses on therapies designed to target cancer cells while also addressing features of the tumor environment that can suppress immune responses. The company’s lead investigational program, ficerafusp alfa (BCA101), is a bifunctional antibody designed to bind EGFR, a protein found on some tumor cells, and block TGF-beta, a signaling protein that can contribute to tumor growth and immune suppression.